Analysts Set Expectations for UroGen Pharma FY2024 Earnings

UroGen Pharma Ltd. (NASDAQ:URGN) – Analysts at HC Wainwright increased their FY2024 earnings estimates for shares of UroGen Pharma in a research report issued on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($3.01) per share for the year, up from their previous estimate of ($3.41). HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q4 2024 earnings at ($0.65) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.70) EPS and FY2025 earnings at ($3.06) EPS.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the previous year, the business posted ($0.68) earnings per share.

URGN has been the topic of a number of other reports. Guggenheim began coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target on the stock. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Finally, Oppenheimer restated an “outperform” rating and set a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, UroGen Pharma currently has an average rating of “Buy” and a consensus target price of $48.38.

UroGen Pharma Trading Up 0.2 %

NASDAQ:URGN opened at $12.12 on Monday. The company has a market cap of $284.21 million, a PE ratio of -3.85 and a beta of 1.12. The company has a current ratio of 9.00, a quick ratio of 7.93 and a debt-to-equity ratio of 4.77. The company has a 50 day simple moving average of $12.75 and a two-hundred day simple moving average of $14.17. UroGen Pharma has a 12 month low of $10.60 and a 12 month high of $20.70.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in URGN. China Universal Asset Management Co. Ltd. lifted its holdings in UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares in the last quarter. Intech Investment Management LLC purchased a new position in UroGen Pharma in the third quarter worth about $155,000. SG Americas Securities LLC bought a new position in shares of UroGen Pharma during the 3rd quarter valued at approximately $179,000. ProShare Advisors LLC purchased a new stake in UroGen Pharma during the 2nd quarter valued at $199,000. Finally, GSA Capital Partners LLP bought a new stake in UroGen Pharma in the third quarter worth $249,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.